Gufic Biosciences receives TGA Australia and ANVISA Brazil approval for Parecoxib 40mg injection
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Subscribe To Our Newsletter & Stay Updated